Pulmonary fibrosis: from pathogenesis to clinical decision-making

Thomas Koudstaal*, Manuela Funke-Chambour, Michael Kreuter, Philip L. Molyneaux, Marlies S. Wijsenbeek

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

9 Citations (Scopus)

Abstract

Pulmonary fibrosis (PF) encompasses a spectrum of chronic lung diseases that progressively impact the interstitium, resulting in compromised gas exchange, breathlessness, diminished quality of life (QoL), and ultimately respiratory failure and mortality. Various diseases can cause PF, with their underlying causes primarily affecting the lung interstitium, leading to their referral as interstitial lung diseases (ILDs). The current understanding is that PF arises from abnormal wound healing processes triggered by various factors specific to each disease, leading to excessive inflammation and fibrosis. While significant progress has been made in understanding the molecular mechanisms of PF, its pathogenesis remains elusive. This review provides an in-depth exploration of the latest insights into PF pathophysiology, diagnosis, treatment, and future perspectives.

Original languageEnglish
Pages (from-to)1076-1087
Number of pages12
JournalTrends in Molecular Medicine
Volume29
Issue number12
Early online date14 Sept 2023
DOIs
Publication statusPublished - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Pulmonary fibrosis: from pathogenesis to clinical decision-making'. Together they form a unique fingerprint.

Cite this